S Eikawa, M Nishida, S Mizukami, C Yamazaki… - Proceedings of the …, 2015 - cir.nii.ac.jp
抄録< jats: title> Significance</jats: title>< jats: p> The multifunctional ability of CTLs is downregulated by interaction between immune-checkpoint molecules expressed on CTLs …
S Eikawa, M Nishida, S Mizukami… - Proceedings of the …, 2015 - europepmc.org
Immune-mediated antitumor effect by type 2 diabetes drug, metformin. - Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools Developers …
S Eikawa, M Nishida, S Mizukami, C Yamazaki… - Proceedings of the …, 2015 - JSTOR
Metformin, a prescribed drug for type 2 diabetes, has been reported to have anti-cancer effects; however, the underlying mechanism is poorly understood. Here we show that this …
S Eikawa, M Nishida, S Mizukami… - Proceedings of the …, 2015 - ui.adsabs.harvard.edu
The multifunctional ability of CTLs is downregulated by interaction between immune- checkpoint molecules expressed on CTLs and their ligands expressed on cancer cells …
S Eikawa, M Nishida, S Mizukami… - … of the National …, 2015 - okayama.elsevierpure.com
抄録 Metformin, a prescribed drug for type 2 diabetes, has been reported to have anti-cancer effects; however, the underlying mechanism is poorly understood. Here we show that this …
S Eikawa, M Nishida, S Mizukami… - Proceedings of the …, 2015 - ncbi.nlm.nih.gov
Immune-mediated antitumor effect by type 2 diabetes drug, metformin - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main …
S Eikawa, M Nishida, S Mizukami… - Proceedings of the …, 2015 - pubmed.ncbi.nlm.nih.gov
Metformin, a prescribed drug for type 2 diabetes, has been reported to have anti-cancer effects; however, the underlying mechanism is poorly understood. Here we show that this …